Is GWPH a good stock to buy?
Table of Contents
Is GWPH a good stock to buy?
Based on analyst ratings, GW Pharma’s 12-month average price target is $220.00. What is GWPH’s upside potential, based on the analysts’ average price target? GW Pharma has 0.47% upside potential, based on the analysts’ average price target.
What is the stock price for GW Pharmaceuticals?
Key Turning Points
| 52-Week High | 219.57 |
|---|---|
| Last Price | 218.96 |
| Fibonacci 61.8% | 168.95 |
| Fibonacci 50% | 153.32 |
| Fibonacci 38.2% | 137.68 |
Is GW Pharmaceuticals publicly traded?
GW Pharmaceuticals shares (GWPH) are listed on the NASDAQ and all prices are listed in US Dollars. GW Pharmaceuticals employs 1,161 staff and has a trailing 12-month revenue of around 0.00.
What happened to GWPH stock?
Jazz Pharmaceuticals (NASDAQ:JAZZ) has officially closed its $7.2B acquisition of GW Pharmaceuticals plc (NASDAQ:GWPH). GW shareholders gave the thumbs up to the deal last month. With the acquisition, Jazz gains access to GW’s cannabinoid portfolio, including Epidiolex, which raked in $510.5M in sales in 2020.
What happened to GW Pharmaceuticals?
DUBLIN , May 5, 2021 /PRNewswire/ — Jazz Pharmaceuticals (Nasdaq: JAZZ) today announced the completion of its acquisition of GW Pharmaceuticals plc (Nasdaq: GWPH) (“GW”), a leader in the science, development and commercialization of cannabinoid-based prescription medicines.
Has GW Pharmaceuticals been sold?
When did GW Pharmaceuticals go public?
May 2013
In May 2013, GW Pharmaceuticals completed an IPO on Nasdaq and raised $31 million by offering 3.5 million shares for $8.90 each.
Who bought GWPH Stock?
Jazz Pharmaceuticals
On Friday, shareholders of GW Pharmaceuticals (GWPH) approved its acquisition by a subsidiary of Jazz Pharmaceuticals (JAZZ -1.02%), both companies announced in a joint press release.
Who bought out GWPH?
Jazz Pharmaceuticals (JAZZ) agreed to buy GW Pharmaceuticals (GWPH) for $7.2 billion on Wednesday — sending GWPH stock to a record high. The deal is expected to close in the second quarter.
Who bought GWPH?
On Friday, shareholders of GW Pharmaceuticals (GWPH) approved its acquisition by a subsidiary of Jazz Pharmaceuticals (JAZZ 1.65%), both companies announced in a joint press release.
What happened to GW Pharma stock?
Does GW Pharmaceuticals still exist?
DUBLIN, May 5, 2021 /PRNewswire/ — Jazz Pharmaceuticals (Nasdaq: JAZZ) today announced the completion of its acquisition of GW Pharmaceuticals plc (Nasdaq: GWPH) (“GW”), a leader in the science, development and commercialization of cannabinoid-based prescription medicines.
Is Jazz Pharmaceuticals an acquisition target?
Corinne Cardina: Another deal that was more recently announced just this week, Jazz Pharmaceuticals announced that they were going to be acquiring GW Pharmaceuticals. That is the British company that has the only FDA-approved CBD derived drug, Epidiolex. Jazz may be a new name for pot investors.
Did GWPH get bought out?
Is jazz a good stock to buy?
Jazz Pharmaceuticals has received a consensus rating of Buy. The company’s average rating score is 2.82, and is based on 9 buy ratings, 2 hold ratings, and no sell ratings.
Does Jazz pharmaceutical pay dividends?
No, Jazz Pharmaceuticals plc does not pay a dividend and therefore does not have such a program.
Will Jazz Pharmaceuticals stock go up?
The 17 analysts offering 12-month price forecasts for Jazz Pharmaceuticals PLC have a median target of 200.00, with a high estimate of 240.00 and a low estimate of 174.00. The median estimate represents a +24.95% increase from the last price of 160.06.
Will JAZZ stock go up?
Based on our forecasts, a long-term increase is expected, the “JAZZ” stock price prognosis for 2027-06-25 is 166.052 USD. With a 5-year investment, the revenue is expected to be around +4.71%. Your current $100 investment may be up to $104.71 in 2027.
Should I buy jazz stock?
There are currently 2 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should “moderate buy” Jazz Pharmaceuticals stock.
Is JAZZ a good buy?
Out of 9 analysts, 3 (33.33%) are recommending JAZZ as a Strong Buy, 4 (44.44%) are recommending JAZZ as a Buy, 2 (22.22%) are recommending JAZZ as a Hold, 0 (0%) are recommending JAZZ as a Sell, and 0 (0%) are recommending JAZZ as a Strong Sell. What is JAZZ’s earnings growth forecast for 2022-2024?
